FDA lists GHK-Cu for injectable routes on its category of bulk drug substances that may present significant safety risks, citing immunogenicity risk from aggregation and limited human data. The peptide has a substantial topical evidence base. The injectable form does not.
Sermorelin and GHK-Cu are frequently discussed together, and they have almost nothing to do with each other. Sermorelin is a GHRH analog that acts on the pituitary to raise growth hormone. GHK-Cu is a copper-binding tripeptide studied for skin and tissue repair. They act on unrelated systems, and no published evidence connects GHK-Cu to the GH axis at all.
- GHK-Cu is glycyl-L-histidyl-L-lysine, a copper-binding tripeptide found naturally in human plasma [1]
- Plasma GHK averages 200 ng/mL at age 20 and declines to about 80 ng/mL by age 60 [1]
- No published evidence links GHK-Cu to growth hormone, IGF-1, or GHRH signaling
- The human evidence for GHK-Cu is topical. Injectable use has no supporting clinical data [4]
- FDA lists injectable GHK-Cu among bulk substances that may present significant safety risks [5]
What GHK-Cu Actually Is
GHK is a naturally occurring tripeptide. It is found in human serum at levels averaging 200 ng/mL at age 20, declining to an average of 80 ng/mL by age 60 [1]. It binds copper with high affinity, and the copper complex is the form studied for tissue repair.
The documented effects are regenerative rather than hormonal. GHK stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, and supports dermal fibroblast function [2], with anti-inflammatory actions, DNA repair, and activation of proteasome-mediated cell cleansing. A gene-expression review reported GHK modulating at least 4,000 human genes [3], and its tissue-remodeling activity extends to lung connective tissue, bone, liver, and stomach lining [6].
The Two Peptides, Side by Side
| Sermorelin | GHK-Cu | |
|---|---|---|
| Class | GHRH analog, 29 amino acids | Copper-binding tripeptide [1] |
| Acts on | GHRH receptors in the anterior pituitary | Fibroblasts, tissue remodeling pathways [2] |
| Primary outcome | Raises GH, then IGF-1 | Collagen, elastin, glycosaminoglycan synthesis [2] |
| Human evidence route | Subcutaneous injection | Topical [3] |
| Affects the GH axis? | Yes, that is the mechanism | No published evidence of any effect |
| On WADA Prohibited List? | Yes, S2.2.4 [7] | Not listed [7] |
| FDA safety-risk category | Not listed | Listed for injectable routes [5] |
The anti-doping classification is a useful independent check. The 2026 WADA Prohibited List names sermorelin explicitly under growth hormone releasing factors [7] and does not mention GHK at all. The body that exists to identify performance-affecting hormonal agents treats only one of these as one.
GHK-Cu Does Not Act on the GH Axis
This is the central point, and it is worth stating plainly because marketing often implies otherwise. There is no published evidence that GHK-Cu raises growth hormone or IGF-1, or interacts with GHRH signaling in any way.
The most detailed review of GHK, covering its effects across roughly 4,000 genes, does not report any effect on growth hormone or IGF-1 signaling [2]. Recent peptide-therapy reviews categorize the two separately, placing GHK-Cu among wound-healing peptides and sermorelin among growth hormone secretagogues [8]. They are not alternatives to one another, and choosing between them is not a meaningful decision.
The Evidence Is Topical. The Product Sold Online Is Injectable
This gap matters more than anything else in the comparison. The human studies behind GHK-Cu are topical applications: facial creams over 12 weeks, eye creams, and thigh creams, in cohorts of roughly 40 to 70 subjects [3]. Those are the trials the marketing claims rest on.
A 2026 review of injectable peptide therapy examined GHK-Cu specifically as an injectable and found no supporting clinical data [4]. So the compound has real evidence, and the product being sold as an injectable is not the form that evidence covers.
FDA places GHK-Cu for injectable routes of administration [5] among bulk drug substances that may present significant safety risks, noting that compounded injectable GHK-Cu may pose risk for immunogenicity due to potential aggregation and peptide-related impurities, and that human safety data are limited. Sermorelin does not appear on that list.
Does Stacking Them Make Sense?
No study has tested the combination. A search of the published literature returns no trial, in humans or animals, combining GHK-Cu with sermorelin or any GHRH analog. Reviews that mention both place them in separate therapeutic categories rather than as a protocol [8].
That is not the same as saying the combination is harmful. Because the mechanisms do not overlap, there is no obvious pharmacologic conflict. But there is also no evidence of benefit, no established dosing, and for the injectable form a specific FDA safety flag [5]. A patient wanting the documented GHK-Cu effects has a better-supported option available: the topical route the evidence actually used.
What This Means in Practice
- If your goal is GH axis restoration, GHK-Cu is not relevant to it
- If your goal is skin quality, the topical evidence is real and the injectable evidence is not [3][4]
- A provider bundling injectable GHK-Cu into a sermorelin protocol should be asked what evidence supports it
- Sermorelin itself increased skin thickness in controlled study, so the GH axis already contributes there
- Check the FDA bulk substances list status at the time you are prescribed anything compounded, since these listings change [5]
GHK-Cu works through a separate pathway, but the sermorelin side of any stack still needs a baseline IGF-1 to be honest. SystemLabs tests IGF-1 before prescribing and formulates sermorelin on clinical indication through a licensed pharmacy.
Frequently Asked Questions
Does GHK-Cu increase growth hormone?
No published evidence supports that. GHK-Cu is a copper-binding tripeptide studied for tissue repair, collagen synthesis, and skin remodeling [2]. The most detailed review of its activity, covering roughly 4,000 genes, reports no effect on growth hormone or IGF-1 signaling [2]. Sermorelin acts on the GH axis; GHK-Cu does not, and they are not substitutes for one another.
Can you take sermorelin and GHK-Cu together?
No published study has tested the combination in humans or animals. Because the mechanisms do not overlap, there is no obvious pharmacologic conflict, but there is also no evidence of added benefit and no established dosing. Note that FDA lists injectable GHK-Cu among bulk substances that may present significant safety risks, citing immunogenicity concerns and limited human data [5].
What is GHK-Cu used for?
The documented effects are regenerative rather than hormonal: stimulating blood vessel and nerve outgrowth, increasing collagen, elastin, and glycosaminoglycan synthesis, supporting dermal fibroblasts, plus anti-inflammatory and DNA repair actions [2]. Human trials behind these claims used topical application, typically facial or eye creams over about 12 weeks [3].
Is injectable GHK-Cu safe?
The human evidence base is topical, not injectable. A 2026 review of injectable peptide therapy examined GHK-Cu and found no supporting clinical data [4]. FDA places GHK-Cu for injectable routes among bulk drug substances that may present significant safety risks, citing potential immunogenicity from aggregation and peptide-related impurities alongside limited human safety data [5]. Discuss that listing with a prescriber before using an injectable form.
Is GHK-Cu banned in sports like sermorelin is?
No. The 2026 WADA Prohibited List names sermorelin explicitly under section S2.2.4, growth hormone releasing factors, prohibited at all times [7]. GHK does not appear anywhere in that document. This reflects the underlying difference: anti-doping authorities classify sermorelin as a GH axis agent and do not classify GHK-Cu as one.
Which is better, sermorelin or GHK-Cu?
The question does not resolve, because they treat different things. Sermorelin targets age-related decline in GH axis function, verified by IGF-1. GHK-Cu targets skin and connective tissue repair, with topical human evidence. If skin quality is the goal, the topical route has the evidence behind it. If GH axis function is the goal, GHK-Cu has no demonstrated role.
References
- The potential of GHK as an anti-aging peptide Aging Pathobiology and Therapeutics, 2020. PMID: 35083444. https://pubmed.ncbi.nlm.nih.gov/35083444/
- Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data International Journal of Molecular Sciences, 2018. PMID: 29986520. https://pubmed.ncbi.nlm.nih.gov/29986520/
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration BioMed Research International, 2015. PMID: 26236730. https://pubmed.ncbi.nlm.nih.gov/26236730/
- Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians The American Journal of Sports Medicine, 2026. PMID: 41476424. https://pubmed.ncbi.nlm.nih.gov/41476424/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. FDA Category 2 bulk substances list. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The human tri-peptide GHK and tissue remodeling Journal of Biomaterials Science, Polymer Edition, 2008. PMID: 18644225. https://pubmed.ncbi.nlm.nih.gov/18644225/
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
- Therapeutic peptides in orthopaedics: applications, challenges, and future directions JAAOS Global Research & Reviews, 2026. PMID: 41490200. https://pubmed.ncbi.nlm.nih.gov/41490200/
